LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

Home・Elenco Azioni・Sangamo Therapeutics Inc

Sangamo Therapeutics Inc

Chiusa

SettoreSettore sanitario

0.17

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

0.17

Massimo

0.17

Metriche Chiave
By Trading Economics
Entrata	-2.5M -37M
Vendite	14M 14M
EPS	-0.111
Margine di Profitto	-262.996
Dipendenti	142
EBITDA	10M -23M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+4515.38% upside

Dividendi
By Dow Jones
Utili prossimi	11 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-51M 74M
Apertura precedente	0.17
Chiusura precedente	0.17

Notizie sul Sentiment di mercato

By Acuity

50%

166 / 347 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bearish Evidence

0.5207 / 0.7223 Supporto e resistenza

Sangamo Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

7 mag 2026, 23:58 UTC

Utili

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

7 mag 2026, 22:57 UTC

Utili

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

7 mag 2026, 23:52 UTC

Utili

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

7 mag 2026, 23:45 UTC

Discorsi di Mercato

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

7 mag 2026, 23:39 UTC

Discorsi di Mercato

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

7 mag 2026, 23:28 UTC

Discorsi di Mercato

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

7 mag 2026, 23:11 UTC

Utili

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

7 mag 2026, 23:06 UTC

Utili

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

7 mag 2026, 23:05 UTC

Utili

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

7 mag 2026, 23:04 UTC

Utili

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

7 mag 2026, 23:03 UTC

Utili

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

7 mag 2026, 23:03 UTC

Utili

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

7 mag 2026, 23:02 UTC

Utili

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

7 mag 2026, 23:00 UTC

Discorsi di Mercato

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

7 mag 2026, 22:45 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

7 mag 2026, 22:45 UTC

Discorsi di Mercato

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

7 mag 2026, 22:42 UTC

Utili

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

7 mag 2026, 22:33 UTC

Utili

Acquisizioni, Fusioni, Takeovers

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7 mag 2026, 22:32 UTC

Utili

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

7 mag 2026, 22:31 UTC

Utili

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

7 mag 2026, 22:31 UTC

Utili

Macquarie: 68% of FY Income From International >MQG.AU

7 mag 2026, 22:30 UTC

Utili

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

7 mag 2026, 22:30 UTC

Utili

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

7 mag 2026, 22:29 UTC

Utili

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

7 mag 2026, 22:28 UTC

Utili

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

7 mag 2026, 22:28 UTC

Utili

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

7 mag 2026, 22:27 UTC

Utili

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

7 mag 2026, 22:27 UTC

Utili

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

7 mag 2026, 22:26 UTC

Utili

Macquarie to End Share Buyback Extended in November>MQG.AU

7 mag 2026, 22:25 UTC

Utili

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Confronto tra pari

Modifica del prezzo

Sangamo Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

4515.38% in crescita

Previsioni per 12 mesi

Media 6 USD 4515.38%

Alto 10 USD

Basso 2 USD

Basato su 2 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Sangamo Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

2 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 2 che hanno fornito valutazioni azionarie a Sangamo Therapeutics Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

0.5207 / 0.7223Supporto e resistenza

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Sentiment

By Acuity

166 / 347 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Sangamo Therapeutics Inc

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.